IV Diclofenac — Competitive Intelligence Brief

IV Diclofenac (IV Diclofenac) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Pain Management, Rheumatology, Gastroenterology.

phase 3 Nonsteroidal anti-inflammatory drug (NSAID) COX-1, COX-2 Pain Management, Rheumatology, Gastroenterology Small molecule

Target snapshot

IV Diclofenac (IV Diclofenac) — Pfizer. Diclofenac inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
IV Diclofenac TARGET	IV Diclofenac	Pfizer	phase 3	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1, COX-2
naproxen sodium codein	naproxen sodium codein	Diskapi Yildirim Beyazit Education and Research Hospital	marketed	NSAID + opioid combination analgesic	COX-1, COX-2, mu opioid receptor
Loxoprofen sodium tablet	Loxoprofen sodium tablet	Sun Yat-sen University	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1, COX-2
Dexketoprofen Trometamol + Paracetamol	Dexketoprofen Trometamol + Paracetamol	Yuzuncu Yil University	marketed	NSAID + analgesic combination	COX-1, COX-2 (dexketoprofen); central prostaglandin synthesis and pain pathways (paracetamol)
Acular LS	Acular LS	University of Colorado, Denver	marketed	Topical NSAID	COX-1, COX-2
EC Aspirin 325	EC Aspirin 325	POZEN	marketed	Antiplatelet agent / NSAID	Cyclooxygenase (COX-1, COX-2)
Paracetamol + ibuprofen	Paracetamol + ibuprofen	Ullevaal University Hospital	marketed	Analgesic/antipyretic combination	COX-1, COX-2 (ibuprofen); prostaglandin synthesis pathway (paracetamol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

1. Università degli Studi di Brescia · 4 drugs in this class
2. Bausch & Lomb Incorporated · 4 drugs in this class
3. Bayer · 3 drugs in this class
4. Pfizer · 3 drugs in this class
5. Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
6. Organon and Co · 3 drugs in this class
7. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
8. Bezmialem Vakif University · 2 drugs in this class
9. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
10. Center For Excellence In Eye Care · 2 drugs in this class